72 results
8-K
EX-99.1
HUMA
Humacyte Inc
22 Mar 24
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
7:06am
presentation titled “Phase 2/3 Study for the Evaluation of Safety and Efficacy of HAV for Vascular Reconstruction in Patients with Limb or Life-Threatening
8-K
EX-1.1
HUMA
Humacyte Inc
4 Mar 24
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
6:53am
) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; and (vi) all other
8-K
EX-99.1
7ike0r2v
29 Feb 24
Other Events
4:02pm
8-K
EX-99.1
3rj5p7 no7b0
12 Sep 23
Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma
7:09am
8-K
EX-99.1
qvizw87hhjkc yb
14 Aug 23
Humacyte Second Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
4s41 sytxxy
12 May 23
Humacyte First Quarter 2023 Financial Results and Business Update
7:13am
8-K
EX-3.2
v6g5tvt4pw2uc t57qb
12 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:04pm
424B3
1yq2or6a4h
12 Aug 22
Prospectus supplement
9:11am
424B3
x5jtrfnmwtq8m it
13 May 22
Prospectus supplement
9:14am